

## Swiss Cancer Institute presentations at ESMO 2025

### Overview

Trial	Type of presentation	First author	Date and time
<b>SCI trials</b>			
SAKK 01/10	Mini oral presentation	Alexandros Papachristofilou	Friday, 17.10.2025, 15:03 - 15:08
SAKK 06/17	Poster	Richard Cathomas	Saturday, 18.10.2025, 12:00-12:45
SAKK 06/19	Poster	Richard Cathomas	Saturday, 18.10.2025, 12:00-12:45
SAKK 16/14	Poster	Sacha I. Rothschild	Saturday, 18.10.2025, 12:00-12:45
<b>Other SCI projects</b>			
Geriatric oncology survey	Poster	Elena D. Chiru	Sunday, 19.10.2025, 12:00-12:45
<b>SCI consulting projects</b>			
Mesothelioma registry	Poster	Laetitia A. Mauti	Saturday, 18.10.2025, 12:00-12:45
<b>Intergroup trials</b>			
AtTEnd/ENGOT-EN7	Proffered paper presentation	Maria Pilar Barretina Ginesta	Sunday, 19.10.2025, 14:55 - 15:05
AtTEnd/ENGOT-EN7	Mini oral presentation	Luca Mazzeola	Sunday, 19.10.2025, 10:15 - 10:20
STAMPEDE	Poster	Mahaz Kayani	Saturday, 18.10.2025, 12:00-12:45
ETOP 25-23 ADOPT-lung	Trials in Progress Poster	Sabine Schmid	Saturday, 18.10.2025, 12:00-12:45
EORTC GUCC 2238 De-escalate	Trials in Progress Poster	Guillaume Grisay	Saturday, 18.10.2025, 12:00-12:45
EORTC 2014-HNCG PROLoNg	Trials in Progress Poster	Irene Braña	Monday, 20.10.2025, 12:00-12:45



### SCI trials

#### **Trial: SAKK 01/10**

Title: Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10

Speaker: Alexandros Papachristofilou

Type of presentation: Mini oral presentation

Number: 1038MO

Date and time: Friday, 17.10.2025, 15:03 - 15:08

Session name: Mini oral session: GU tumours, prostate, penile and testis

Place: Heidelberg Auditorium - Hall 6.2

#### **Trial: SAKK 06/17**

Title: Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Final analysis of the single arm phase II trial SAKK 06/17

Speaker: Richard Cathomas

Type of presentation: Poster

Number: 3106P

Date and time: Saturday, 18.10.2025, 12:00-12:45

#### **Trial: SAKK 06/19**

Title: Intravesical recombinant BCG followed by perioperative chemo-immunotherapy (chemo-IO) for patients with muscle-invasive bladder cancer (MIBC): Interim analysis of SAKK 06/19 study

Speaker: Richard Cathomas

Type of presentation: Poster

Number: 3107P

Date and time: Saturday, 18.10.2025, 12:00-12:45

#### **Trial: SAKK 16/14**

Title: Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy in the trial SAKK 16/14

Speaker: Sacha I. Rothschild

Type of presentation: Poster

Number: 1835P

Date and time: Saturday, 18.10.2025, 12:00-12:45



### Other SCI projects

#### **Topic: Geriatric oncology survey**

Title: Understanding geriatric oncology in Switzerland: Results of a nationwide assessment

Speaker: Elena D. Chiru

Type of presentation: Poster

Number: 2907P

Date and time: Sunday, 19.10.2025, 12:00-12:45

### Intergroup trials

#### **Trial: AtTEnd/ENGOT-EN7**

Title: Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Speaker: Maria Pilar Barretina Ginesta

Type of presentation: Proffered paper presentation

Number: LBA39

Date and time: Sunday, 19.10.2025, 14:55 - 15:05

Session name: Proffered paper session: Gynaecological cancers

Place: Heidelberg Auditorium - Hall 6.2

#### **Trial: AtTEnd/ENGOT-EN7**

Title: WES-derived aneuploidy score (W-AS) identifies MMRd patients with reduced benefit from immunotherapy in endometrial cancer: Multi-omic analysis of the phase III AtTEnd/ENGOT-EN7 trial

Speaker: Luca Mazzarella

Type of presentation: Mini oral presentation

Number: LBA40

Date and time: Sunday, 19.10.2025, 10:15 - 10:20

Session name: Mini Oral session: Gynaecological cancers

Place: Cologne Auditorium - CityCube A

#### **Trial: STAMPEDE**

Title: On-treatment serum prostate specific antigen (PSA) and metastatic burden at treatment start: landmark analysis of 7129 patients starting long-term androgen deprivation (ADT) and randomised in the STAMPEDE platform protocol

Speaker: Mahaz Kayani

Type of presentation: Poster



Number: 2478P

Date and time: Saturday, 18.10.2025, 12:00-12:45

**Trial: ETOP 25-23 ADOPT-lung**

Title: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with resectable NSCLC

Speaker: Sabine Schmid

Type of presentation: Trials in Progress Poster

Number: 1803TiP

Date and time: Saturday, 18.10.2025, 12:00-12:45

**Trial: EORTC GUCG 2238 De-escalate**

Title: EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors

Speaker: Guillaume Grisay

Type of presentation: Trials in Progress Poster

Number: 2519TiP

Date and time: Saturday, 18.10.2025, 12:00-12:45

**Trial: EORTC 2014-HNCG PROLoNg**

Title: EORTC 2014-HNCG PROLoNg: Pembrolizumab and radiotherapy for oligometastatic squamous cell carcinoma of the head and neck, randomized phase III trial

Speaker: Irene Braña

Type of presentation: Trials in Progress Poster

Number: 1443TiP

Date and time: Monday, 20.10.2025, 12:00-12:45

SCI Consulting projects

**Project: Mesothelioma registry**

Title: SLFN11 expression as potential prognostic marker in pleural mesothelioma

Speaker: Laetitia A. Mauti

Type of presentation: Poster

Number: 2970P

Date and time: Saturday, 18.10.2025, 12:00-12:45